218 related articles for article (PubMed ID: 31990837)
1. An oral drug for chronic lymphocytic leukemia.
Koehler A
JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837
[TBL] [Abstract][Full Text] [Related]
2. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
3. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
Aarup K; Rotbain EC; Enggaard L; Pedersen RS; Bergmann OJ; Thomsen RH; Frederiksen M; Frederiksen H; Nielsen T; Christiansen I; Andersen MA; Niemann CU
Eur J Haematol; 2020 Nov; 105(5):646-654. PubMed ID: 32736410
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S; Giannarelli D; Baumann T; Montserrat E
Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
[No Abstract] [Full Text] [Related]
7. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
8. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
Gribben JG; Bosch F; Cymbalista F; Geisler CH; Ghia P; Hillmen P; Moreno C; Stilgenbauer S
Br J Haematol; 2018 Mar; 180(5):666-679. PubMed ID: 29318593
[TBL] [Abstract][Full Text] [Related]
9. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
[No Abstract] [Full Text] [Related]
10. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
Mato AR; Clasen S; Pickens P; Gashonia L; Rhodes J; Svoboda J; Hughes M; Nabhan C; Ali N; Schuster S; Carver J
Cancer Biol Ther; 2018 Jan; 19(1):1-2. PubMed ID: 29281559
[TBL] [Abstract][Full Text] [Related]
11. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Ruppert AS; Booth AM; Ding W; Bartlett NL; Brander DM; Coutre S; Brown JR; Nattam S; Larson RA; Erba H; Litzow M; Owen C; Kuzma CS; Abramson JS; Little RF; Smith SE; Stone RM; Byrd JC; Mandrekar SJ; Woyach JA
Leukemia; 2021 Oct; 35(10):2854-2861. PubMed ID: 34274940
[TBL] [Abstract][Full Text] [Related]
12. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
Stephens DM; Byrd JC
Blood; 2019 Mar; 133(12):1298-1307. PubMed ID: 30642919
[TBL] [Abstract][Full Text] [Related]
13. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
[No Abstract] [Full Text] [Related]
14. Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
Gallais F; Ysebaert L; Despas F; De Barros S; Obéric L; Allal B; Chatelut E; White-Koning M
Clin Pharmacol Ther; 2021 Jul; 110(1):220-228. PubMed ID: 33539551
[TBL] [Abstract][Full Text] [Related]
15. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Langerbeins P; Zhang C; Robrecht S; Cramer P; Fürstenau M; Al-Sawaf O; von Tresckow J; Fink AM; Kreuzer KA; Vehling-Kaiser U; Tausch E; Müller L; Eckart MJ; Schlag R; Freier W; Gaska T; Balser C; Reiser M; Stauch M; Wendtner CM; Fischer K; Stilgenbauer S; Eichhorst B; Hallek M
Blood; 2022 Jan; 139(2):177-187. PubMed ID: 34758069
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
[No Abstract] [Full Text] [Related]
17. Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis.
Ciuculete DC; Popescu RA; Dan GA
Rom J Intern Med; 2021 Sep; 59(3):270-277. PubMed ID: 33913303
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
İskender G; İskender D; Ertek M
Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
[No Abstract] [Full Text] [Related]
19. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
20. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
